Description
The in vitro diagnostics (IVD) market has demonstrated robust growth, driven by technological advancements and expanding opportunities. Diagnostic testing has evolved from merely diagnosing illnesses to providing critical insights for precision medicine treatments. Although COVID-19 testing has declined, it continues to contribute to overall revenues in 2024. The market remains dynamic, influenced by new product developments, shifts in global health spending, regulatory changes, and disease trends, maintaining its resilience.
Several segments within the IVD market are experiencing significant growth and attracting industry attention. These include Point-of-Care (POC) testing, cancer diagnostics, companion diagnostics, immunochemistry, and mass spectrometry. Additionally, nucleic acid assays, gene testing, and HPV molecular diagnostics are poised for substantial growth, marking them as key areas of interest for the future.
Diagnostic testing is now a cornerstone of healthcare, aiding in both diagnosis and treatment decisions. Despite the decline in COVID-19 testing, core diagnostic segments have shown consistent growth. The market’s evolution is driven by factors such as innovative products, global health expenditure changes, regulatory shifts, and emerging disease trends.
Key growth areas include next-generation sequencing (NGS), personalized medicine, and mass spectrometry. Immunochemistry, POC testing, and molecular diagnostics are also expected to play crucial roles in the future of IVD. The market is characterized by continuous innovation and adaptation.
The report In Vitro Diagnostic (IVD) Trends and Market Update: December 2024 by Kalorama Information provides the latest insights into these trends and other factors shaping the market. It covers:
- Drivers of growth in the IVD market in 2024
- Major trends impacting the market in 2024
- Product trends and new developments shaping the IVD market in 2024
Highlighted trends from Q3 2023 to Q3 2024 include:
- The increasing role of AI technologies in IVD development and testing
- Exponential growth in the POC diabetes market
- Double-digit growth in HPV molecular testing
- Significant growth in blood banking molecular NAT screening due to advancements in nucleic acid method
Table of Contents
Chapter 1: Worldwide IVD Market – December 2024 Update
IVD Market Demand and Growth
- Figure 1-1: Q1 2024 – Q3 2024 Segment Performance Commentary
- Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) (Clinical Chemistry; Immunoassays – non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c – lab; Hematology – Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology – Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular – NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
- Figure 1-2: IVD Segment Performance, Q1 2024 – Q4 2024 estimated ($ million) (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other)
- Figure 1-3: IVD Segment Performance, Total Market Value, 2024 estimated ($ million) (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other)
COVID-19 Diagnostic Markets
- Table 1-2: COVID-19 Product Sales, by Segment, 2024 ($ million) (Immunoassay [Antigen and Serology], Molecular, Rapid [POC Professional and POC At-Home])
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market excluding and with COVID-19, 2024 ($ million)
- Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) (IVD Market excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments)
- Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, Q1 2024 – Q4 2024 estimated ($ million)
- Table 1-4: Global In Vitro Diagnostic Market – YoY Growth, 2023-2024 (%) (Clinical Chemistry; Immunoassays – non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c – lab; Hematology – Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology – Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular – NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
- Figure 1-6: Global In Vitro Diagnostic Market – YoY Growth, 2023-2024 (%) (Clinical Chemistry; Immunoassays – non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c – lab; Hematology – Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology – Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular – NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
Chapter 2: Product Trends and New Developments
Selected New – Q3 2024 – Core IVD Product Launches, Developments and Trends
Flow Cytometry
Immunoassay
Molecular
Personalized Medicine
POC
Sequencing
Selected COVID-19 Developments – Q3 2024
- Figure 2-1: COVID-19 Test Market, by Type, Q1 2024 – Q4 2024 estimated ($ million) (Antigen, Molecular, Rapid, Serology)
Antigen/Antibody
Molecular
Chapter 3: Top IVD Market Participant Results
Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth, by Leading Competitors, Change in Sales, 2023-2024 (%) (Abbott Diagnostics, Becton Dickinson, bioMérieux, Danaher, Dexcom, Exact Sciences, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific)
- Figure 3-2: Top 10 IVD Companies: Changes in Market Distribution for IVD Sales, 2021-2024 estimated – Roche and Abbott Battle for #1 Spot (%) (Abbott Diagnostics, Becton Dickinson, bioMérieux, Danaher, Dexcom, Exact Sciences, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific)
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
Q3 M&A Activity
- Table 3-1: Q3 2024 Merger and Acquisition Activity
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
bioMérieux SA
- Table 3-4: bioMérieux Corporate Summary
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
Dexcom, Inc
- Table 3-6: Dexcom Corporate Summary
Exact Sciences
- Table 3-7: Exact Sciences Corporate Summary
Roche Diagnostic
- Table 3-8: Roche Diagnostic Corporate Summary
Siemens Healthineers
- Table 3-9: Siemens Healthineers Corporate Summary
Sysmex Corporation
- Table 3-10: Sysmex Corporate Summary
Thermo Fisher Scientific
- Table 3-11: Thermo Fisher Scientific Corporate Summary
Chapter 4: New Opportunities
AI in Liquid Biopsy
- Table 4-1: Selected AI/Liquid Biopsy Initiatives
Antimicrobial Resistance
Single Molecule Analyzer
New Guidance for Lipid Panels
Telehealth
